Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05938725 · ClinicalTrials.gov registry record · Phase 1

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

A Phase 1 study of Lupus Nephritis and Lupus Nephritis - WHO Class IV, sponsored by Kyverna Therapeutics.

Active
Registry status
Phase 1
Development phase
6
Enrollment target
6
Study locations

NCT05938725: Active Phase 1 study of Lupus Nephritis and Lupus Nephritis - WHO Class IV, sponsored by Kyverna Therapeutics.

NCT05938725 is a Phase 1 study of Lupus Nephritis and Lupus Nephritis - WHO Class IV that is active but no longer recruiting, run by Kyverna Therapeutics. The registered enrollment target is 6 participants, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05938725, a Phase 1 study of Lupus Nephritis and Lupus Nephritis - WHO Class IV, is active but no longer recruiting, sponsored by Kyverna Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
6 participants
Enrollment target
6
Study locations

Study Summary

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis

Conditions Studied

Lupus Nephritis Lupus Nephritis - WHO Class IV Lupus Nephritis - World Health Organization (WHO) Class III

Interventions

  • BIOLOGICAL KYV-101 anti-CD19 CAR-T cell therapy
  • DRUG Standard lymphodepletion regimen

Study Locations (6)

California

  • Stanford University Medical Center - Palo Alto

Colorado

  • University of Colorado - Denver

Massachusetts

  • University of Massachusetts Worcester - Worcester

New York

  • Northwell Health - Great Neck

Ohio

  • Ohio State University Wexner Medical Center - Columbus

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2023-04-28
Est. Completion 2027-08
Phase Phase 1
Kyverna Therapeutics

6 total trials

What the registry record for NCT05938725 still lists

NCT05938725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which KYV-101 anti-CD19 CAR-T cell therapy is the first listed.

NCT05938725 lists 6 locations in 6 states (California, Colorado, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT05938725 about?

NCT05938725 is a clinical study titled "KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis". A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis

What is the current status of trial NCT05938725?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-04-28. Estimated completion is 2027-08.

What conditions does trial NCT05938725 study?

This clinical trial studies the following conditions: Lupus Nephritis, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III.

What interventions are being tested in trial NCT05938725?

The interventions under investigation include: KYV-101 anti-CD19 CAR-T cell therapy (BIOLOGICAL), Standard lymphodepletion regimen (DRUG).

Who is sponsoring clinical trial NCT05938725?

This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05938725 being conducted?

This trial has 6 study locations across California, Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Nephritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05938725's enrollment target sits among peer trials

6 30th of 30 the lowest of 30 other Lupus Nephritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05938725, the US trial registry maintained by the National Library of Medicine. NCT05938725 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.